The Norwegian Immunotherapy in Multiple Myeloma Study (NIMMS)

St. Olavs Hospital

Status: Enrolling

Conditions: AL Amyloidosis; Plasma Cell Leukemia; Myeloma Multiple

Treatments: Biological: Idecabtagene vicleucel; Drug: Talquetamab; Biological: Ciltacabtagene Autoleucel; Drug: Teclistamab; Drug: Elranatamab

Study type: Observational

Funder types: Other

Identifiers

NCT06855121

NIMMS

Details and patient eligibility

About

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Participants age ≥ 18 years

• Prior diagnosis of one of the following

  • Multiple myeloma as defined according to IMWG criteria
  • Primary plasma cell leukemia as defined according to IMWG consensus definition
  • AL-amyloidosis as defined according to IMWG criteria

• Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):

  • Teclistamab (Tecvayli)
  • Elranatamab (Elrexfio)
  • Talquetamab (Talvey)
  • Idecabtagene vicleucel (ide-cel/Abecma)
  • Ciltacabtagene autoleucel (cilta-cel/Carvykti)

Exclusion Criteria:

• None